A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Compugen LTD stock. As of the latest transaction made, Two Sigma Advisers, LP holds 18,484 shares of CGEN stock, worth $26,432. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,484
Holding current value
$26,432
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.56 - $2.1 $28,835 - $38,816
18,484 New
18,484 $33,000
Q1 2024

May 15, 2024

SELL
$1.75 - $2.95 $139,475 - $235,115
-79,700 Reduced 37.4%
133,384 $344,000
Q4 2023

Feb 14, 2024

SELL
$0.53 - $2.0 $43,935 - $165,794
-82,897 Reduced 28.01%
213,084 $421,000
Q3 2023

Nov 14, 2023

SELL
$0.88 - $1.31 $67,410 - $100,349
-76,603 Reduced 20.56%
295,981 $275,000
Q2 2023

Aug 14, 2023

SELL
$0.57 - $1.38 $122,414 - $296,371
-214,762 Reduced 36.56%
372,584 $424,000
Q1 2023

May 15, 2023

SELL
$0.68 - $1.11 $360,901 - $589,119
-530,738 Reduced 47.47%
587,346 $411,000
Q4 2022

Feb 14, 2023

SELL
$0.58 - $1.2 $131,370 - $271,800
-226,500 Reduced 16.85%
1,118,084 $805,000
Q3 2022

Nov 14, 2022

BUY
$0.66 - $2.32 $794,574 - $2.79 Million
1,203,900 Added 855.75%
1,344,584 $883,000
Q2 2022

Aug 15, 2022

BUY
$1.57 - $3.33 $60,288 - $127,872
38,400 Added 37.54%
140,684 $260,000
Q1 2022

May 16, 2022

SELL
$2.76 - $4.64 $87,492 - $147,088
-31,700 Reduced 23.66%
102,284 $329,000
Q4 2021

Feb 14, 2022

BUY
$4.09 - $7.16 $85,890 - $150,360
21,000 Added 18.59%
133,984 $576,000
Q3 2021

Nov 15, 2021

BUY
$5.8 - $8.02 $313,780 - $433,882
54,100 Added 91.88%
112,984 $675,000
Q2 2021

Aug 16, 2021

SELL
$6.87 - $9.16 $399,147 - $532,196
-58,100 Reduced 49.66%
58,884 $488,000
Q1 2021

May 17, 2021

BUY
$7.67 - $13.77 $819,033 - $1.47 Million
106,784 Added 1046.9%
116,984 $1.01 Million
Q4 2020

Feb 16, 2021

BUY
$12.07 - $17.95 $123,114 - $183,090
10,200 New
10,200 $124,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $124M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.